It’s Just Common Sense!

As informed shoppers, we check ingredients and make choices in what we wish to purchase every time we go to the grocery store.

If the FDA can require carbohydrate and fat content on a package of cookies, why shouldn’t the public know when aborted fetal or embryonic cell components and DNA are being injected into their bodies?

A Moral Duty – A Civil Right!

In June 2005, the Vatican stated there was a “grave duty to use alternatives.” In 2006 the Catholic Medical Association issued a formal resolution stating that moral alternatives MUST be used. And while most vaccines offer ethical versions, unless we know our options up-front, how can we choose them?

In addition, 48 of 50 states allow religious exemptions. If parents are not given foreknowledge of morally problematic vaccines, their civil rights are violated!

Tell Congress to pass this sensible legislation!

For More Information
Visit Our Website
www.cogforlife.org

Click on the link for
The Fair Labeling And Informed Consent Act

Or Contact Us At
Children of God for Life
4613 Barfield Crescent Rd
Murfreesboro, TN 37128
Phone (615) 898-1070

- Release Date Sept 2008 –
Copying Permissible

“Informed consumers are essential to the fair and efficient functioning of a free market economy. Packages and their labels should enable consumers to obtain accurate information and should facilitate value comparisons. Therefore, it is hereby declared to be the policy of the Congress to assist consumers and manufacturers in reaching these goals in the marketing of consumer goods.”

(US Code, Title 15, Chapter 39 §1451)
Background
In August of 2003, Australia passed legislation that ensures consumers have the right to know when human embryonic stem cells or materials are used in the manufacture or testing of pharmaceutical products.

Since regulatory requirements for labeling do not give this same protection to Americans, Children of God for Life introduced the Fair Labeling and Informed Consent Act (FLICA) to members of Congress.

The proposed legislation would provide concise information to all consumers and members of the medical profession whenever aborted fetal or embryonic material is used in a product so that alternatives may be selected in advance of purchase.

Fair Competition
FLICA opens the market to the others in the industry who are willing to provide alternatives. FLICA stimulates the economy with new jobs, new products and restores consumer confidence in government and the industry.

Existing Law Supports It!
Current Federal Law requires clear, non-evasive language in consumer packaging under:
- 21 CFR Title 21 Part 201
- 42 USC, § 300aa-26
- USC Title 15, Ch. 39, §1451

But the law as written is vague. Under FLICA, two changes are required: The manufacturer’s Package Insert and the Vaccine Information Statement must be amended to protect physicians and consumers.

Protecting Physicians
Package inserts are not only included with the product but are also published in the annual Physician’s Desk Reference, thus giving foreknowledge to medical professionals. Also, under the Doctrine of Informed Consent, physicians are required to provide patients with all relevant information about a proposed procedure including the nature of the procedure, the risks, the benefits and available alternative treatments.

Amending The Package Insert
Revising the package insert would require two simple actions by lawmakers:
- Revise the manufacturer insert with the addition of 3 words: “from elective abortion” next to any aborted fetal materials listed in the ingredients section.
- Add one paragraph to 502 (e) of the Federal Food Drug and Cosmetic Act authorizing the above requirement

Amending the VIS: Protecting All Consumers And Physicians With Informed Consent
The VIS (Vaccine Information Statement) is already required under Federal Law to be given to patients prior to vaccination. Two changes would be needed:
- Amending 42 USC §300aa-26 to include any product using aborted fetal cell or embryonic material
- Revision of the VIS adding one paragraph informing the patient of the use of aborted fetal or embryonic material in the product and if other options are available.